Boston Therapeutics, Inc. (OTCMKTS:BTHE) shares passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.02 and traded as low as $0.02. Boston Therapeutics shares last traded at $0.03, with a volume of 13,407 shares trading hands.
The company’s 50 day moving average price is $0.03 and its two-hundred day moving average price is $0.02. The firm has a market cap of $3.33 million, a PE ratio of -1.50 and a beta of -0.16.
Boston Therapeutics Company Profile (OTCMKTS:BTHE)
Boston Therapeutics, Inc, a pre-clinical and clinical-stage pharmaceutical development company, focuses on the development, manufacture, and commercialization of carbohydrate-based therapeutic drugs and dietary supplements in the United States. Its lead pharmaceutical drug candidates are BTI-320, a non-systemic carbohydrate-based compound that is in Phase IIb clinical trial to reduce post-meal elevation of blood glucose levels in Type 2 diabetic and pre diabetic patients; BTI-410, a peptide injectable compound that has completed Phase Ib clinical trials for type 1 immunosuppression therapy after kidney transplant surgery and type 2 diabetes patients; and IPOXYN, a carbohydrate-based injectable drug to prevent necrosis, or cell death, as well as to treat hypoxic conditions, such as diabetic foot ulcers and other vascular/neurological complications.
Featured Article: Why do analysts give a neutral rating?
Receive News & Ratings for Boston Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.